Analyst Ratings For NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE)
Today, Needham & Company LLC raised its price target on NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE) to per share.
Some recent analyst ratings include
- 3/14/2018-BMO Capital Markets Reiterated Rating of Outperform .
- 5/2/2016-UBS initiated coverage with a Buy rating.
- 5/2/2016-Wells Fargo initiated coverage with a Outperform rating.
Recent Insider Trading Activity For NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE)
NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE) has insider ownership of 27.00% and institutional ownership of 47.43%.
- On 12/8/2017 Anthony G Quinn, CEO, bought 8,288 with an average share price of $4.96 per share and the total transaction amounting to $41,108.48.
- On 12/6/2017 Anthony G Quinn, CEO, bought 4,888 with an average share price of $4.92 per share and the total transaction amounting to $24,048.96.
- On 12/5/2017 Charles N York II, CFO, bought 25,959 with an average share price of $4.48 per share and the total transaction amounting to $116,296.32.
- On 12/4/2017 Anthony G Quinn, Director, bought 7,956 with an average share price of $4.98 per share and the total transaction amounting to $39,620.88.
- On 12/1/2017 Anthony G Quinn, Director, bought 4,100 with an average share price of $4.53 per share and the total transaction amounting to $18,573.00.
- On 12/1/2017 Charles N York II, CFO, bought 6,500 with an average share price of $4.59 per share and the total transaction amounting to $29,835.00.
- On 2/21/2017 Orbimed Advisors Llc, Major Shareholder, bought 109,300 with an average share price of $5.16 per share and the total transaction amounting to $563,988.00.
Recent Trading Activity for NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE)
Shares of NASDAQ:AGLE – Aeglea Bio Therapeutics closed the previous trading session at 10.28 down -0.08 0.75% with 10.281900405883789 shares trading hands.